Perkins Capital Management Inc. Sells 1,007,078 Shares of Biodesix, Inc. $BDSX

Perkins Capital Management Inc. lessened its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX) by 95.0% during the third quarter, Holdings Channel.com reports. The firm owned 52,633 shares of the company’s stock after selling 1,007,078 shares during the quarter. Perkins Capital Management Inc.’s holdings in Biodesix were worth $397,000 at the end of the most recent quarter.

Separately, XTX Topco Ltd raised its position in Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares during the last quarter. 20.96% of the stock is owned by institutional investors and hedge funds.

Biodesix Trading Up 5.8%

NASDAQ BDSX opened at $11.74 on Monday. The stock has a market capitalization of $93.45 million, a P/E ratio of -2.11 and a beta of 0.60. The business has a 50 day simple moving average of $7.63 and a 200 day simple moving average of $7.66. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84. Biodesix, Inc. has a one year low of $3.44 and a one year high of $21.80.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. The firm had revenue of $21.77 million for the quarter, compared to analysts’ expectations of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. Research analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Biodesix has an average rating of “Moderate Buy” and an average target price of $32.50.

Biodesix Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.